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Interleukin-18 as a drug 
repositioning opportunity for 
inflammatory bowel disease: A 
Mendelian randomization study
Lauren E. Mokry1,2, Sirui Zhou1,2, Cong Guo3, Robert A. scott3,5, Luke Devey4, 
Claudia Langenberg5, Nick Wareham5, Dawn Waterworth6, Lon Cardon6, Philippe Sanseau3, 
George Davey Smith7 & J. Brent Richards  1,2,8,9,10
Support from human genetics increases the probability of success in drug development. However, 
few examples exist of successful genomically-driven drug repositioning. Given that a Mendelian 
form of severe enterocolitis is due to up-regulation of the interleukin-18 (IL18) signaling pathway, 
and pharmacologic inhibition of IL18 has been shown to reverse this enterocolitis, we undertook 
a Mendelian randomization study to test the causal effect of elevated IL18 levels on inflammatory 
bowel disease susceptibility (IBD) in 12,882 cases and 21,770 controls. Mendelian randomization 
is an established method to assess the role of biomarkers in disease etiology in a manner that 
minimizes confounding and prevents reverse causation. Using three SNPs that explained almost 7% 
of the variance in IL18 level, we found that each genetically predicted standard deviation increase 
in IL18 was associated with an increase in IBD susceptibility (odds ratio = 1.22, 95% CI = 1.11–1.34, 
P-value = 6 × 10−5). This association was further validated in 25,042 IBD cases and 34,915 controls (odds 
ratio = 1.13, 95% CI = 1.05–1.20). Recently, an anti-IL18 monoclonal antibody, which decreased free 
IL18 levels, was found to be safe, yet ineffective in a phase II trial for type 2 diabetes. Taken together, 
these genomic findings implicated IBD as an alternative indication for anti-IL18 therapy, which should 
be tested in randomized controlled trials.
The majority of drug development programs fail to produce medicines that gain regulatory approval1,2. This is 
most often due to lack of efficacy, rather than poor safety profiles2, leading to the suggestion that drug target iden-
tification and validation may be more successful using human genetics, since such an approach can offer direct 
insight into the perturbation of putative targets in humans. Indeed, recent evidence demonstrates that medicines 
aimed at therapeutic targets supported with human genetic evidence are more likely to gain regulatory approval 
than therapies lacking such support3,4.
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is an 
inflammatory condition of the gastrointestinal tract for which there are many associated genetic loci5,6, but few 
available medications supported by human genetics data. The etiology of IBD remains poorly understood and as 
consequence approximately one-fifth of patients are unable to achieve remission using current therapies7. Recent 
evidence suggests that the members of the interleukin (IL) 1 family (including IL1α, IL1β, IL18 and IL33), which 
are established regulators of gastrointestinal inflammation, could influence IBD risk8.
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Natural experiments from human genetics in the form of Mendelian disease, where proteins in the interleukin 
pathways have been altered due to rare mutations, lend support to this hypothesis. First, gain of function muta-
tions in NLCR4 (an important regulator of epithelial inflammasomes) lead to severe and chronic elevations in 
IL18 and also to early onset enterocolitis9,10. This suggests that IL18 could be a mediator of NLCR4-associated 
early onset enterocolitis. Human experimental evidence further supports this hypothesis. Recently, a child car-
rying a gain-of-function NLCR4 mutation, developed severe enterocolitis and extremely elevated IL18 levels. 
The child was treated with recombinant IL18 binding protein, which decreased free IL18 levels to undetectable 
levels, impaired IL18 signaling, and resolved the severe enterocolitis11. In individuals with non-Mendelian forms 
of IBD, fresh intestinal biopsy samples demonstrated higher expression of IL18 levels in intestinal epithelial cells 
relative to controls12. This is concordant with evidence from murine models which found that knocking out IL18 
signaling was protective against colitis and mucosal damage13. Thus evidence from Mendelian genetics, cellular 
expression studies and murine models all provide evidence of a role for IL18 signaling in intestinal inflammation. 
However, it is not yet fully understood whether common genetic perturbations of IL18 signaling can lead to 
increased susceptibility to IBD, the most common form of inflammatory enterocolitis.
We therefore tested whether variation in IL18 levels in the general population was causally associated with risk 
of IBD. To do so, we employed Mendelian randomization (MR) methods. MR has been used extensively to pro-
vide evidence to strengthen inference regarding causality of biomarkers, such as IL18, in disease etiology14. Under 
the assumptions of MR, if IL18 is causal in IBD pathology, then the genetic determinants of IL18 should influence 
disease risk (Fig. 1). A main advantage of the MR approach is that potential for confounding is greatly limited 
since allele assignment is randomized at conception, thus breaking potential association with confounders, much 
like the process of randomization in randomized controlled trials. Further, allele assignment always precedes 
disease onset, and is unaltered by it, thereby preventing reverse causation, where the disease itself influences the 
level of the exposure being studied.
If IL18 levels were causally related to an increased risk of IBD, this may have an immediate clinical impact 
since an IL18 inhibitor, GSK1070806, is already in development. GSK1070806 was developed for type 2 diabetes 
and recently tested in a phase II clinical trial which demonstrated a favourable safety profile, but failed to show 
any clinically relevant effects on glucose metabolism15. Evidence from MR may indicate whether this IL18 inhib-
itor could be repositioned to IBD.
Methods
Data sources. To investigate whether IL18 levels influence IBD susceptibility, we undertook a two-sample 
MR approach16 where summary statistics were selected from separate GWASs of IL18 levels17 and IBD risk6. 
An updated GWAS of IL18 levels18 and a recent larger IBD meta-analysis19 were also included for replication 
purposes. In addition, since disease severity may provide greater insight for drug target validation, we selected 
summary statistics from a recent GWAS of CD prognosis20. We selected summary statistics of SNPs that were 
genome-wide significant for IL18 levels (p < 1.2 × 10−9, which accounted for multiple testing cytokines) in recent 
a GWAS study of 41 cytokine traits involving up to 8,293 individuals of Finnish ancestry17. Corresponding effect 
estimates on IBD risk were obtained from the International IBD Genetics Consortium, which is the largest GWAS 
published to date for IBD (N = 12,882 cases, 21,770 controls)6. For the MR analysis of CD progression we selected 
summary statistics from a recently published CD prognosis GWAS using 1762 and 972 CD cases of poor and 
good prognosis respectively20. The methods of these GWAS are described in detail elsewhere6,17,20.
Mendelian randomization analyses. MR has been used extensively to interrogate the role of modifiable 
risk factors in disease etiology14,21,22. In brief, the two-sample MR approach allows summary statistics to be used 
from separate GWAS for an exposure (such as IL18) and an outcome (such as IBD)16. This provides important 
advantages over traditional MR studies, where exposure and the outcome are measured in the same cohort, since 
summary statistics can be used from the largest genotyped cohorts of the exposure and outcome respectively. MR 
estimates for each SNP are then produced by the ratio method, where the SNP’s effect on IBD is weighted by its 
effect on IL1816. Individual MR estimates can then be combined using a fixed effects model to provide a summary 
measure23,24. To reduce the possibility of population stratification, we selected summary statistics from European 
Figure 1. Directed Acyclic Graph. This figure displays the MR study design. Confounders are that are factors 
associated with both IL18 level and risk of IBD, yet do not lie in the causal pathway between IL18 and IBD. 
When confounding factors are unknown, or not adequately adjusted for in observational analyses, they bias 
estimates of the association between IL18 and IBD. In MR analyses, SNPs that influence IL18 level are tested 
for their effect on IBD instead of IL18 measurements. Since SNPs are randomized at conception, this breaks 
association with potentially confounding variables and allows for an estimate of the effect on IL18 on IBD risk.
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ancestry-only analyses. We also performed a replication two-sample MR using exposure and outcome derived 
from different GWAS18,19. The summary statistics used for this analysis are publicly available and can be down-
loaded from their respective consortia’s website.
We performed sensitivity analyses to test the assumptions of MR and to assess for differential effects of IL18 
across UC and CD. MR estimates were recalculated using the methods described above using summary statistics 
for only rs71478720, which lies in the IL18 gene and thus reduces the possibility pleiotropy biasing our results. 
Separate MR analyses were also performed for UC (N = 6,968 cases, 20,464 controls) and CD (N = 5,956 cases, 
14,927 controls) respectively to assess for differential effects.
Since a monoclonal antibody for IL18 was previously tested in a phase II clinical trial for the treatment of T2D 
but failed to demonstrate efficacy, we sought to address whether MR analyses supported a role of IL18 in T2D 
risk. We used summary statistics from a large meta-analysis including samples from DIAGRAM, the UKBiobank 
and the EPIC-InterAct study (up to N = 26 903 T2D cases and 198 269 controls)25. We also performed a CD 
severity MR using summary statistics from the recently published GWAS for CD prognosis (N = 1762 poor prog-
nosis and N = 972 CD good prognosis)20.
Methods for evaluating the association of IBD at the IL18 receptor locus. There are additional 
lines of evidence implicating a role for IL18 in the etiology of IBD: SNPs within the IL18 receptor locus, harbor-
ing IL18R1 (the Interleukin 18 Receptor 1) and IL18RAP (the IL18 receptor accessory protein) have also been 
associated with IBD26–28. To identify putative regulatory variants, we filtered variants in strong LD (R2 > 0.8) that 
resided within gene regulatory elements. Putative regulatory elements were defined by DNaseI hypersensitivity, 
H3K4me1, and H3K27ac in CD14, CD34, small intestine, and gastric tissues. The chromatin mark data was 
obtained from the ENCODE and Roadmap Epigenomics projects29–31. eQTL information for all associated var-
iants was downloaded from the GTEx project32. All data was visualized using the UCSC Genome Browser33,34.
Colocalisation Analyses. Biomarker MR studies may generate false positive associations when the causal 
SNP that influences the exposure is in linkage disequilibrium (LD) with a separate causal SNP that influences 
the outcome. It is therefore helpful to understand if there is a strong at separate signal at the locus which is in LD 
with the instrumental variable. Nevertheless, we undertook colocalization analysis using the coloc package35 and 
inspected the colocalisation plots to identify any potential confounding by LD.
Phenome-Wide MR Study. To explore potential adverse effects of IL18 inhibition, we undertook MR 
analyses of all available outcomes on MR Base, an online repository and software package enabling simultane-
ous MR studies across multiple outcomes. We corrected for multiple testing using a Bonferroni correction of 
P < 0.05/386436.
Results
Mendelian randomization analysis of IL18 levels on IBD susceptibility. Three SNPs were 
genome-wide significant (P < 1.2 × 10−9, accounting for multiple testing) for IL18 levels in the cytokine GWAS 
(N = 3,636): rs17229943 (OCLN), rs385076 (NLRC4) and rs71478720 (IL18) (Table 1)17. These three independent 
SNPs combined to explain 6.8% of the variation in IL18 levels17.
Two of the three variants have a mechanistic link to IL18 level. rs385076 is an intronic variant that maps to 
the NLRC4 locus. As described above, this gene product is an important regulator of inflammosomes and IL18 
level11,37. rs71478720 lies in the intron of IL18 and has been shown to influence IL18 expression in multiple 
tissues (including lung, pancreas, thyroid, skin and skeletal muscle) in the Genotype-Tissue Expression project 
(GTEx)32,38. rs17229943 is an intronic variant that lies near the occludin gene (OCLN). OCLN encodes an integral 
membrane protein important for the formation of tight junctions, but the mechanism in which it influences IL18 
level remains unclear39.
Corresponding effect estimates of the same IL18 increasing alleles on risk of IBD were obtained from the 
International IBD Genetics Consortium, which is the largest GWAS published to date for IBD (N = 12,882 cases, 
21,770 controls)6. Given this sample size and the fact that a relatively large proportion of variation in IL18 levels 
were attributed to these three SNPs, we had 100% statistical power to detect a 20% increase in odds of IBD per 
standard deviation increase in IL1840. All three IL18-increasing alleles were found to confer an increase in odds of 
IBD in the International IBD Genetics Consortium GWAS and IL18-increasing alleles at rs71478720 (IL18) and 
rs385076 (NLCR4) were individually associated with an increased risk of IBD (Table 1)17.
MR estimates were calculated by weighting each SNP’s effect on IBD by its effect on IL18. Each independent 
MR estimate demonstrated an effect of IL18 on risk of IBD (Fig. 2). When all three estimates were combined 
using a fixed effects model, we obtained a summary odds ratio of 1.22 (95% CI = 1.11–1.34, p-value = 5.9 × 10−5, 
Locus SNP Chr IL18 increasing Allele Allele Frequency
IL18 Resultsa IBD Resultsb
Effect on IL18 (SD) p-value OR (95% CI) p-value
NLRC4 rs385076 2 C 0.64 0.243 1.7 × 10−22 1.05 (1.02–1.09) 0.0051
OCLN rs17229943 5 C 0.05 0.312 1.6 × 10−11 1.07 (0.97–1.18) 0.066
IL18 rs71478720 11 C 0.76 0.267 3.1 × 10−22 1.05 (1.01–1.09) 0.012
Table 1. Characteristics of SNPs used as instrumental variables. aeffect size and p-value selected from the 
cytokine GWAS17. bOR (95% CI) and p-value selected from the IBDGenetics Consortium6.
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I2 = 0%, 95% CI = 0–90%) per genetically predicted standard deviation increase in IL18. This evidence supports 
the hypothesis that increased IL18 levels increase risk of IBD.
Assessment of Mendelian randomization assumptions. One important assumption of MR is that 
the chosen SNPs do not have effects on the outcome independent of the exposure (i.e. a lack of pleiotropy). 
Therefore to test for the presence of pleiotropy, we performed a sensitivity analysis where only rs71478720 (IL18) 
was used to calculate an MR estimate. Given that rs71478720 lies in an intron for IL18 and influences expression 
of IL18 in multiple tissues32,38, this greatly reduces the possibility of pleiotropy since it is likely that this SNP acts 
directly through IL18 level. The MR estimate using this single SNP was similar to our meta-analysis (OR = 1.21, 
95% CI = 1.05–1.40, p-value = 0.011), suggesting that our results were not substantially biased due to pleiotropy. 
Given that the cytokine signaling network is highly-correlated, we also queried whether the three IL18 SNPs asso-
ciated with any of the other 40 cytokine traits tested in Ahola-Olli et al.17. Interestingly, only rs71478720 at IL18, 
was found be associated with interferon gamma-induced protein 10 (IP10) once corrected for multiple testing 
(p < 0.05/41 = 0.0012) (Supplementary Table 1). rs71478720 (IL18) exhibited a relatively small effect on ILP10 
level (beta = 0.09, 95% CI = 0.037–0.14 p-value = 8.97 × 10−4) compared to its effect on IL18 l (beta = 0.27, 95% 
CI = 0.21–0.32, p-value = 3.71 × 10−22). Since rs71478720 acts as a cis-eQLT for IL18, it is likely that this SNP 
influences IL18 expression, which in turn modulates ILP10 level, given that IL18 itself has been shown to induce 
expression of interferon-gamma41.
Replication MR analysis. Two genome-wide significant SNPs (surviving multiple corrections in both 
discovery and replication study) for IL18 levels in the cardiovascular disease biomarker GWAS were selected 
(N = 3,394): rs75649625 (IL18) and rs693918 (SRD5A2)18 (Supplementary Table 2). These two independent SNPs 
collectively explain 3.8% of the variation in IL18 levels. The estimates of IL18 increasing alleles for each SNP on 
risk of IBD were replicated using the latest IBD meta-analysis (N = 25,042 cases, 34,915 controls)19. Power calcu-
lation estimated that we had 99% statistical power to detect a 20% increase in odds of IBD per standard deviation 
increase in IL18.
Independent MR estimates of each SNP were calculated by weighting their effect on IBD by its effect on IL18 
(Supplementary Fig. 1). We then combined the independent estimates using an inverse‐variance weighted model 
and obtained a summary odds ratio of 1.13 (95% CI = 1.05–1.20, p-value = 0.0021) per genetically predicted 
standard deviation increase in IL18, which replicated our initial MR findings.
Separate Mendelian randomization analyses for CD and UC. We next tested whether this associa-
tion with IL18 level was more pronounced in CD compared to UC. Meta-analyses investigating CD and UC as 
separate outcomes demonstrated a consistent effect of IL18 (ORCrohn’s = 1.15, 95% CI = 1.01–1.31, p-value = 0.041; 
ORUC = 1.25, 95% CI = 1.11–1.42, p-value = 2.39 × 10−4). This effect persisted for UC when only rs71478720 
(IL18) was analyzed (OR = 1.26, 95% CI = 1.05–1.51, p-value = 0.012). For CD, the IL18-only analysis demon-
strated the same direction of effect, however given the 95% confidence intervals, we cannot rule out no effect of 
IL18 on CD risk (OR = 1.10, 95% CI = 0.90–1.34, p-value = 0.37).
Mendelian randomization analyses of IBD severity. These above MR findings reflect effects of IL18 on 
disease incidence and not disease progression since the GWAS for IBD employed a case-control design. As such, 
using summary statistics from an IBD susceptibility GWAS may not be the most appropriate method for drug 
target validation if interventions aim to treat the effects of the disease rather than prevention42. Since a relatively 
small GWAS (N = 2,734 CD cases) was recently published on CD prognosis20, we employed MR to interrogate the 
effect of IL18 on CD severity. We obtained inconclusive results (OR = 1.06, 95% CI = 0.77–1.46, p-value = 0.74, 
I2 = 0%, 95% CI = 0–90%) (Supplementary Fig. 2), which likely reflects low statistical power due to a relatively 
small sample size. In addition, progression MR analyses are prone to collider-bias, where the selection of cases 
can lead to a spurious inverse association with potential confounders43. This potential was demonstrated in the 
CD prognosis GWAS given that an inverse genetic correlation (as measured by LD score regression) was obtained 
for CD susceptibility and prognosis, although this correlation was estimated with wide 95% confidence intervals.
The association of IBD and the IL18 receptor locus. The strongest association with IBD, rs917997 
(P = 3.00 × 10−20, OR = 1.10)26, is found near the 5′ end of IL18RAP (Supplementary Fig. 3). The index SNP along 
with six other SNPs that are in near perfect LD reside within putative regulatory elements and promoters defined 
Figure 2. Forest Plot of the Results of the IL18-IBD MR Analysis. Forest plot of results where the boxes and 
confidence bars represent the individual MR estimates of the IL18 SNPs on IBD. The red diamond represents 
the summary estimate where all three SNPs were combined using a fixed effects model.
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by open chromatin, active histone, and transcription factor binding sites in immune cell types (Supplementary 
Fig. 3, Supplementary Table 3). In blood cells, these SNPs are also eQTLs for IL18R1 and IL18RAP in the GTEx 
database (P = 1.4 × 10−5 and P = 7.3 × 10−29, respectively). These observations implicate IL18R1 and IL18RAP as 
effectors of the association at these loci and further support the involvement of the IL18 pathway in IBD.
Mendelian randomization analyses of IL18 levels and type 2 diabetes susceptibility. Given 
that the previously published trial for IL18 inhibition in type 2 diabetes failed to demonstrate efficacy, we tested 
whether IL18 levels were causally associated with an increased risk of type 2 diabetes using the same MR meth-
ods described above. By using 26,903 individuals with type 2 diabetes and 198 269 controls, we found that MR 
analyses did not support a role of IL18 in type 2 diabetes risk (OR = 1.05, 95% CI = 0.99–1.13, P-value = 0.12) 
(Supplementary Fig. 4). Similar results were obtained in a previous MR study interrogating different but corre-
lated SNPs (R2 > 0.05) mapping to IL18 locus44. Therefore the MR of IL18 on type 2 diabetes is consistent with 
trial results and suggests that further investigation of this therapy for type 2 diabetes may not be successful. 
However, we note that again the GWAS for type 2 diabetes provided SNP-associations for susceptibility, rather 
than progression.
Possible adverse effects of IL18 inhibition. To provide insights into potential side-effects of IL18 inhi-
bition, we queried the three IL18 SNPs and proxies (R2 > 0.8) using PhenoScanner and MR base36,45, to under-
stand if these SNPs were strongly associated with other traits that may produce adverse effects. Full results from 
PhenoScanner and MR base are provided in Supplementary Table 4 and Supplementary Dataset 1 respectively. 
Briefly our search on PhenoScanner demonstrated that none of the SNPs, or available proxies, were genome-wide 
significant for any trait other than IL18. rs385076 was nominally (p < 0.05/3 = 0.017) associated with depressive 
symptoms and overweight status, while rs71478720 was nominally associated with type 2 diabetes and fasting 
glucose. Information for rs17229943 was not available on PhenoScanner. In addition, we performed a hypoth-
esis free MR of IL18 levels on all outcomes available on MR base. None of the results of these MR analyses were 
significant once we corrected for multiple testing (p < 0.05/3864 = 1.29 × 10−5). The results of these analyses are 
reported in Supplementary Dataset 1.
Colocalisation. Inspection of colocalisation plots (Supplementary Fig. 5) showed no evidence of separate 
association signals for IL18 or IBD at the three instrumental variable loci which may have confounded our 
analyses.
Phenome-Wide MR. Exploring for potential side-effects of IL18 inhibition we performed phenome-wide 
MR and identified no potential additional associations surviving Bonferroni correction.
Discussion
Thus, our MR analyses support a role of IL18 in IBD susceptibility, with each genetically predicted stand-
ard deviation increase in IL18 conferring a 22% increase in odds of IBD (OR = 1.22, 95% CI = 1.11–1.34, 
p-value = 5.9 × 10−5). These findings may have an important clinical impact, given that anti-IL18 therapy 
(GSK1070806) was recently tested for the treatment of T2D, and considered safe, but ineffective. Further the 
results of our MR analysis of IL18 on T2D susceptibility were concordant with these trials results, providing addi-
tional evidence for the value of genetics to predict drug target success.
These findings have clinical relevance. First, epidemiological studies have indicated that the incidence of IBD 
is increasing across populations46. While there are many drugs indicated for the treatment of IBD, these drugs 
have varying degrees of efficacy to induce and maintain disease remission7,47–49. Targeting IL18 may provide 
benefit to IBD patients and our findings support investigating this question in clinical trials. However, while 
GSK1070806, was found to be well-tolerated among subjects with type 2 diabetes assigned to active treatment, the 
side effect profiles in IBD patients may be different. Further, given the small sample size of the phase II study and 
duration of therapy, the long-term adverse outcomes of GSK1070806 are not known. GSK1070806 is currently 
being tested in phase II clinical trials for renal transplantation50. This trial will better assess the tolerability and 
safety of GSK1070806 given the elevated risk of this patient.
This study has several limitations. Pleiotropy is a potential source of bias in MR studies and can be difficult 
to account for since the exact function of many genetic variants is unknown. However our MR estimate using 
only the IL18 intronic variant is unlikely to be substantially influenced by pleiotropy since this has been shown to 
influence the expression of IL18 in multiple tissues. While this variant was nominally associated with IP10 in the 
cytokine GWAS, it is unclear whether this small effect upon IP10 level is independent of IL18. GTEx results indi-
cate that rs71478720 (IL18) acts as a cis-eQTL for IL18 in multiple tissues, but importantly this did not include 
the colon, the most relevant tissue type for IBD. This may possibly be attributed to a small sample size (N = 124), 
or other technical issues such as cell-type variability and ascertainment. For instance there may be differences in 
IL18 expression in intestinal epithelial versus smooth muscle cells not evaluated in GTEx. For our analysis, we 
cannot rule out possible bias due to residual European population stratification since summary estimates for IL18 
were obtained from Finnish population whereas IBD estimates includes multiple European subgroups. Such bias 
would only occur if ancestry also associated IBD susceptibility. While the epidemiological evidence has demon-
strated a north-west/south-east gradient for IBD, with the highest burden observed in the Nordic countries and 
the United Kingdom, it is unclear whether this is due to genetic factors or rather reflects variability in reporting 
and detection among the wealthier European nations51. Future GWAS of cytokine levels in other European pop-
ulations can confirm our results. We also note that results of our CD progression MR were inconclusive. As data 
from large disease progression GWASs becomes increasingly available, this will enable MR to further validate 
effective drug targets.
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Taken together, several lines of evidence strongly implicate a role for IL18 in IBD. These now include MR evi-
dence demonstrating important effects of IL18 on IBD risk in the general population, Mendelian gain-of-function 
mutations leading to increased IL18 levels and severe enterocolitis, which was reversed by IL18 signaling inhibi-
tion, cis-eQTLs for IL18 receptors leading to increased IBD risk and finally intestinal biopsies from IBD patients 
showing increased IL18 expression in epithelial cells. Future clinical trials investigating anti-IL18 therapies for 
the treatment of IBD should help to test the utility of these approaches to identify clinically relevant drug targets 
for this important disease.
Data Availability
All data necessary to perform this MR analysis is included in Table 1 of the manuscript. Full summary statistics 
for the cytokine GWAS are available at: http://computationalmedicine.fi/data#Cytokine_GWAS. Dataset used for 
replication are available at: https://doi.org/10.5281/zenodo.264128. Full summary statistics for the IBD GWAS 
are available for download from the International IBD Genetics Consortium’s website at: https://www.ibdgenet-
ics.org/downloads.html. Dataset used for replication are available at: ftp://ftp.sanger.ac.uk/pub/project/humgen/
summary_statistics/human/2016-11-07/.
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